What is Precision Biologics?
Founded in 2012, Precision Biologics, Inc. operates as a clinical-stage biotechnology enterprise dedicated to the early detection and treatment of malignant tumors. The company distinguishes itself through a specialized focus on antibody therapeutics and diagnostics that prioritize tumor-specific targeting while sparing healthy cellular tissue. By integrating breakthrough biotechnological advancements with its proprietary vaccine platform, Precision Biologics is effectively redefining the standard of care in oncology. The company's market position is bolstered by a rigorous research and development framework that has consistently demonstrated efficacy in human clinical trials, positioning it as a high-value player in the competitive biotech landscape.
How much funding has Precision Biologics raised?
Precision Biologics has raised a total of $73.1M across 6 funding rounds:
Private Equity
$5.3M
Multiple Rounds
$14.6M
Private Equity
$53.1M
Debt
$150K
Private Equity (2012): $5.3M, investors not publicly disclosed
Private Equity (2013): $3.3M, investors not publicly disclosed
Unspecified (2013): $10.5M, investors not publicly disclosed
Private Equity (2013): $795K, investors not publicly disclosed
Private Equity (2015): $53.1M, investors not publicly disclosed
Debt (2020): $150K with participation from PPP
Key Investors in Precision Biologics
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Precision Biologics?
Looking ahead, Precision Biologics is poised to leverage its recent capital influx to scale its clinical operations and expedite the regulatory pathway for its lead therapeutic candidates. The strategic focus remains on the refinement of its antibody-based diagnostic tools, which are essential for the early identification of oncological markers. As the company moves forward, stakeholders anticipate further data readouts from ongoing trials, which will be instrumental in determining the commercial viability of its vaccine platform. The firm's long-term growth strategy involves deepening its intellectual property portfolio and exploring potential partnerships to enhance the global distribution of its life-saving medical technologies.
See full Precision Biologics company page
